Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2023-05-05 00:00:00 ET · period of report 2023-05-04 · accession 0001209191-23-027601 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-05 | 2023-05-04 | RARE | Parschauer Karah Herdman | EVP, CLO | S - Sale | $45.00 | -4,378 | 52.0K | -8% | -$197.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-04 | S | D | 4,378 | $45.00 | 51,982 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. (F3) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. (F2) Includes 221 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023. |